PharmaCyte Biotech annual gross margin
2011
2012
2013
PharmaCyte Biotech Gross Margin Growth & History (PMCB)
PharmaCyte Biotech's gross margin was 20.89% for fiscal 2013.
View full PharmaCyte Biotech company overviewPharmaCyte Biotech annual gross margin history
| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2013 | 2013-04-30 | 20.89% | −49.99 pp |
| 2012 | 2012-04-30 | 70.88% | −3.64 pp |
| 2011 | 2011-04-30 | 74.52% | — |
PharmaCyte Biotech quarterly gross margin
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| Q2 2013 | 2012-10-31 | −53.01% | −122.60 pp |
| Q1 2013 | 2012-07-31 | 100.00% | +79.32 pp |
| Q4 2012 | 2012-04-30 | 167.94% | +68.61 pp |
| Q3 2012 | 2012-01-31 | 89.09% | +57.73 pp |
| Q2 2012 | 2011-10-31 | 69.58% | −12.43 pp |
| Q1 2012 | 2011-07-31 | 20.68% | −53.63 pp |
| Q4 2011 | 2011-04-30 | 99.33% | — |
| Q3 2011 | 2011-01-31 | 31.36% | — |
| Q2 2011 | 2010-10-31 | 82.02% | — |
| Q1 2011 | 2010-07-31 | 74.31% | — |
PharmaCyte Biotech gross margin trends
Between the periods ended 2011-04-30 and 2013-04-30, PharmaCyte Biotech's gross margin decreased from 74.52% to 20.89%, a change of −53.63 percentage points. The latest reported quarter, Q2 2013, shows −53.01%.
About the metric
What gross margin means
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
Calculation and source
How gross margin is calculated
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review PharmaCyte Biotech source filings ↗